RTP Mobile Logo
Gastrointestinal Cancer Update, Issue 1, 2016 (Video Program)
Released January 2017

Proceedings from video interviews with Drs Jaffer A Ajani and Robert J Mayer on the treatment of gastrointestinal cancers. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists-oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gastrointestinal (GI) cancers.

    Colorectal cancer (CRC) is a common and potentially lethal type of cancer, and its clinical management is continuously evolving. Although “non-CRC” GI tumors are less frequently encountered individually, the cancer-related deaths in that subcategory surpass those attributed to CRC. Published results from ongoing trials continuously lead to the emergence of novel biomarkers and new therapeutic targets and regimens, thereby altering existing management algorithms. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of these advances. To bridge the gap between research and patient care, Gastrointestinal Cancer Update uses one-on-one discussion with leading GI oncology investigators. By providing access to the latest scientific developments and the perspectives of experts in the field, this CME activity assists medical oncologists with the formulation of up-to-date management strategies.


    • Appraise recent data on therapeutic advances and changing practice standards in colorectal and gastric cancer, and integrate this information, as appropriate, into current clinical care.
    • Develop a long-term care plan for individuals diagnosed with metastatic CRC, considering the patient’s biomarker profile, exposure to prior systemic therapy, symptomatology, performance status and personal goals for treatment.
    • Use HER2 status, clinical factors and patient perspectives to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric/gastroesophageal cancer.
    • Appraise the rationale for and clinical data with investigational anti-PD-1 and/or anti-PD-L1 antibodies in patients with CRC or gastric cancer.
    • Assess available data with currently approved and investigational agents with documented activity in gastroesophageal cancer, and develop a clinical algorithm for optimal patient care, including the option of participating in clinical research.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    CME credit is no longer available for this issue

    Successful completion of this CME activity enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
    CME credit is no longer available for this issue

    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GICU116/Video/CME.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jaffer A Ajani, MD
    Professor of Medicine
    Department of Gastrointestinal Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Lilly, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology; Other Remunerated Activities: Genentech BioOncology.

    Robert J Mayer, MD
    Faculty Vice President for Academic Affairs
    Dana-Farber Cancer Institute
    Stephen B Kay Family Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Therapeutics, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. 

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Boston Biomedical Pharma Inc, Lilly and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: January 2017
    Expiration date: January 2018

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Selection and Sequencing of Therapy for Patients with Newly Diagnosed Metastatic Colorectal Cancer (mCRC)
  • FOLFOX versus FOLFIRI with or without bevacizumab as first-line therapy for mCRC
  • A 52-year-old man with metastatic pan-wild-type rectal cancer
  • Role of EGFR monoclonal antibodies in pan-wild-type mCRC
  • First-line treatment for patients with BRAF-mutant mCRC
Later-Line Management of Progressive mCRC
  • Dosing and clinical utility of regorafenib
  • Tolerability and predictors of response to TAS-102 in mCRC
  • Cancer stemness inhibitor BBI608 in mCRC
Current and Future Treatment of Gastroesophageal Cancer
  • Joint ASCO/College of American Pathologists/American Society of Clinical Pathology guidelines on HER2 testing for gastric or gastroesophageal cancer
  • Epidemiology and prognosis of HER2-positive gastric cancer
  • GATSBY trial: T-DM1 versus a taxane as second-line therapy for metastatic gastric or gastroesophageal cancer
  • Continuation of anti-HER2 therapy after disease progression in the first-line setting
  • A 53-year-old man with HER2-positive, metastatic gastric cancer who received a durable response with chemotherapy and trastuzumab
  • Incorporating ramucirumab into the treatment of metastatic gastric cancer
  • Evaluation of cancer stem cell inhibitors as a novel treatment approach
  • Postoperative chemotherapy versus chemoradiation therapy after neoadjuvant therapy for gastric cancer
  • New understanding of Barrett’s esophagus
Checkpoint Inhibitors in Gastrointestinal Cancers
  • Mismatch repair deficiency and response to anti-PD-1 treatment
  • Evaluation of mismatch repair deficiency in patients with mCRC
  • Microsatellite instability status and response to anti-PD-1 treatment in gastric cancer
  • Activity of immune checkpoint inhibitors in squamous cell carcinoma of the esophagus